Medicinal vegetable extract classification under Chapter 30 supported interim waiver of disputed duty and penalty in an excise case.
Compound vegetable extracts used in Ayurvedic medicine may, on a prima facie view, fall under Chapter 30 rather than Chapter 13 where they have therapeutic or prophylactic value and have not undergone fermentation or other preservative processes. The tariff scheme, HSN Explanatory Notes, and the cited departmental circular support the view that such mixed or compounded extracts are not treated as Chapter 13 goods, and that Note 1(d) excludes medicaments classifiable under Chapter 30. In the interim relief context, the admitted duty on simple single-plant extracts was to be deposited, while pre-deposit and recovery were waived for the disputed compound-extract duty and penalty.
Issues: (i) Whether compound vegetable extracts obtained in the manufacture of Ayurvedic medicines were, on a prima facie view, non-marketable goods or classifiable as medicaments under Chapter 30 rather than under Chapter 13 of the Central Excise Tariff Act, 1985. (ii) Whether the applicants were entitled to waiver of pre-deposit and stay of recovery in respect of duty and penalty, while admitting liability on simple vegetable extracts.
Issue (i): Whether compound vegetable extracts obtained in the manufacture of Ayurvedic medicines were, on a prima facie view, non-marketable goods or classifiable as medicaments under Chapter 30 rather than under Chapter 13 of the Central Excise Tariff Act, 1985.
Analysis: The relevant tariff structure, the HSN Explanatory Notes to Chapter 13 and Chapter 30, and the departmental circular relied upon all indicated that liquid vegetable extracts which have not undergone fermentation or other preservative processes are not marketable, and that mixed or compounded vegetable extracts having therapeutic or prophylactic value are classifiable under Chapter 30. Note 1(d) to Chapter 13 excludes medicaments falling under Chapter 30, and medicinal compound vegetable extracts obtained by treating a mixture of plants are treated as Chapter 30 products.
Conclusion: The applicants made out a strong prima facie case that compound vegetable extracts were not to be treated as goods under Chapter 13 and were, on the materials then available, classifiable under Chapter 30.
Issue (ii): Whether the applicants were entitled to waiver of pre-deposit and stay of recovery in respect of duty and penalty, while admitting liability on simple vegetable extracts.
Analysis: The applicants accepted duty liability on simple extracts obtained from a single plant and undertook to deposit that amount. For compound extracts, the prima facie classification issue supported waiver of the demand at the interim stage, and the same approach extended to the penalty demand. The proper course was therefore to secure only the admitted duty on simple extracts and protect the applicants from pre-deposit and recovery for the disputed component pending appeal.
Conclusion: Pre-deposit of duty on compound extracts and pre-deposit of penalty were waived, recovery was stayed, and only the admitted duty on simple extracts was required to be deposited within the time granted.
Final Conclusion: The interim application succeeded in part by granting protection against pre-deposit and recovery for the disputed compound-extract demand and penalty, while leaving intact the obligation to pay the admitted duty on simple extracts.
Ratio Decidendi: For interim relief in excise classification disputes involving medicinal vegetable extracts, compound extracts having therapeutic or prophylactic value and not subjected to preservative processes may be treated as prima facie classifiable under Chapter 30, supporting waiver of pre-deposit and stay of recovery for the disputed demand.